At Revere, we are developing small molecule drugs targeting Rac1 and its genomic variants, members of the Ras-homologous (Rho) family of GTPases. These key signaling proteins function as molecular switches which are commonly dysregulated in many cancers and other diseases, including chronic kidney disease, viral infections such as COVID-19, and Alzheimer’s disease.
Our customized drug discovery and development platform enables us to address the diverse mechanisms of Rac1 GTPase hyperactivation to treat cancer and other conditions with significant unmet clinical needs.
